|
deCODE genetics, Inc. - Company Profile Snapshot
| Company Profile: |
deCODE genetics, Inc. |
| Ticker: |
DCGN |
| Exchanges: |
NAS |
| 2008 Sales: |
58,095,000 |
| Major Industry: |
Miscellaneous |
| Sub Industry: |
Medical Services |
| Country: |
UNITED STATES |
| Employees: |
331 |
Business Description
deCODE genetics, Inc.. The Group's principal activity is to develop and market products to improve the treatment, diagnosis and prevention of common diseases. It applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. Its lead drug development programs include: DG041 for the prevention of arterial thrombosis. The products include deCODE T2TM, deCODE AFTM, deCODE MITM, deCODEmeTM, deCODEProstateCancerTM, deCODE GlaucomaTM, deCODE BreastCancerTM. Other DNA-based risk diagnostic tests currently in development include: melanoma, basal cell cancer, bladder cancer and lung cancer.
|
Not the Report you are looking for?
Click here for more browsing options.
|
The following information is available to subscribers or can be accessed by purchasing the Company Profile Report:
|
- Address (mailing), Phone Number, Web Address
- Earnings/Dividends
- Employees
- Exchanges Listed
- Financial Ratio Analysis |
- Recent Stock Performance
- Sales (recent year)
- Senior Officers
- Shareholder Information
- Stock Analysis Summary |
Layout and Content of a Typical Report
|
|
|
|
|
